Canadian Respiratory Journal (Jan 2015)
Effectiveness of Phosphodiesterase-5 Inhibitor Therapy for Portopulmonary Hypertension
Abstract
BACKGROUND: Portopulmonary hypertension is associated with significant morbidity and mortality. Phosphodiesterase-5 inhibitor therapy is efficacious in other causes of WHO group I pulmonary arterial hypertension.